Phil: I don't use Facebook, but the 1 billion shares is a done deal. The initial use of such shares will likely be new management Stock Option Plan and awards. The SEC settlement will come next followed by the R/S and new shares sold to raise capital. This is how I see the events unfolding. Certainly it would make sense to hold off on the R/S until the stock price is in double digits, a very likely event once the SEC matter is settled and the updated clinical trials report is issued. That is the ideal timing for the R/S as I see it.
Gary was a speaker at the 2013 World Stem Conference somewhere in California and this was not announced as in the past. I suspect the reason is that this type event was news in the past as there was no other news of substance. Now however, I believe we are very close to major news with the trials final patients all injected and preliminary findings being written up for dissemination. Keep in mind that any publication of trial related results must be reviewed by multiple parties and approved by the safety board so this has taken time thus accounting for the trial news blackout. Although SEC rules require meaningful and important information to be disclosed via an 8K filing, it must be done following FDA sensitivites as well. Once they have all this information distilled and ready, we will be on the rocket launching pad for sure. Be patient as some Christmas presents are worth the wait. The SEC settlement announcement will be dwarfed by the Clinical Trials results.
Keep-I thought you were more on the ball than your post indicates. ACTC has 2.7 billion shares (soon 3.7 billion) o/s vs. 128 million of Gern that works out to 22x and 29x more shares than Gern. Adjusted for this share ratio the price of ACTC would be $1.34 @ 22x and $1.77 @ 29x so there really is no comparison. Gern has 66 million in cash, ACTC is broke. Having said that, I think that ACTC has very strong upward potential if they get to Phase II and given a priority by the FDA to accelerate the trials.
All must keep in mind that the new shares authorized will allow additional option shares to be granted so that once the reverse split comes about, the ACTC team does not get diluted like the loyal shareholders. Until this happens, likely before year end and concurrent with Dr. Lanza's new contract, not major news will be released. Having a value for options based on a value of six cents per share is better than fifteen or twenty cents a share, that's for sure. Sad story for shareholders but very true I'm afraid.
Don't you realize how much downward pressure your stupid .045 bid puts on the stock you idiot? You are keeping a lid on the stocks' ability to advance moron. You're not an investor or a believer in the science being developed by this copy you monkey brain.
Phil: Interesting response from you. I suspect that Wow may be wishing or speculting on a news release based on comments made long ago by Gary that there was an FDA meeting on Nov. 22. Look at it this way,let's hope he is right and thankful his post wasn't about some political BS.
Just what we need on this board, another complete moron like you.
Thank you Gary for a call that reported absolutely nothing to shareholders and the investment community. Press release on less than 24 hours notice with no news, why have a call at all. Now that you have your extra billion shares for executive incentive programs, stop with the empty promises and get things moving faster or we are all DOA in the not too distant future.
Respectfully disagree Freddy. This is no way to manage a Company sitting on a science volcano. There must be constant focus on the science to offset all the negative legacy issues that have beat down the value of ACTC while at the same time playing into the hands of the market manipulators.
This is the real reason the stock is doing nothing in terms of increased value. The one billion additional shares announcement is the only news item that affected value............pushing the share price down. No patient news updates since spring, no news on EU trials, no news on litigation, no news on SEC settlement progress amazes and concerns me. Gary, you and your PR advisors need to wake up and generate some excitement about the ACTC science and stop the focus on lining your own pockets with additional shares on the come. This is not 5 card draw poker. Investors in ACTC deserve better from you for their patience and loyalty.
Sentiment: Strong Buy
Elk: We (ACTC) is a dual track entity, one with amazing science, the other with amazing incredible legacy problems. Information realted to either, independently or jointly, will have positive impact if the news is good. Alternatively, if things go worse than already factored into the stock, we're all in trouble.
Sentiment: Strong Buy
His behavior and lack of follow-up on public statements, especially those so critical and related to the clinical trials seems to support your characterization of him.
In August, Gary stated on the CC that the delay in getting final patients injected was due to screening process and compounded by Europe being on vacation until September. He was confident that injections would all get done by mid to late September for early results updates in mid-October, before the annual meeting vote or call. Nothing in the way of an update was ever provided since on the trials or patients for that matter of significance. He just wanted his option plan shares to be there for their new incentive program for management. What a insult to all long-term ACTC shareholders who truly deserve better than this type of treatment from the likes of Gary.